A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE)
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities
Sponsor: Biogen
Terminated
Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
This PHASE2 trial investigates Alzheimer's Disease and Cognitive Dysfunction and is currently terminated or withdrawn. Biogen leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE2
▶ Show 11 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2020 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2020 — Sep 2020 [monthly]
Terminated PHASE2
-
Dec 2019 — May 2020 [monthly]
Terminated PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
May 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .